Rivaroxaban versus enoxaparin in pediatric venous thromboembolism: experience in a hemostasis center


Maria Landwehr Lardelli, M.D.
Vall d'Hebron University Hospital
Barcelona, Spain

Venous thromboembolism (VTE) is rare but increasingly recognized in pediatric patients, especially those who have been hospitalized. In this presentation, Maria Landwehr Lardelli reports results from a monocentric, retrospective study comparing rivaroxaban and enoxaparin in children with imaging-confirmed VTE. The EINSTEIN-Jr program led to the approval of rivaroxaban for treating and preventing pediatric VTE. This study included 172 patients treated between 2017 and 2024. Enoxaparin was associated with a twofold higher recurrence rate of VTE compared to rivaroxaban, while safety outcomes were comparable.

Previous Article Essential role of VWF-aIIbß3 binding in thrombus stability in vessel injury
Next Article Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress